We synthesized a novel, multi-functional, radiosensitizing agent by covalently linking 6-fluoro-6-deoxy-D-glucose (6-FDG) to gold nanoparticles (6-FDG-GNPs) via a thiol functional group. We then assessed the bio-distribution and pharmacokinetic properties of 6-FDG-GNPs in vivo using a murine model. At 2 h, following intravenous injection of 6-FDG-GNPs into the murine model, approximately 30% of the 6-FDG-GNPs were distributed to three major organs: the liver, the spleen and the kidney. PEGylation of the 6-FDG-GNPs was found to significantly improve the bio-distribution of 6-FDG-GNPs by avoiding unintentional uptake into these organs, while simultaneously doubling the cellular uptake of GNPs in implanted breast MCF-7 adenocarcinoma. When combined with radiation, PEG-6-FDG-GNPs were found to increase the apoptosis of the MCF-7 breast adenocarinoma cells by radiation both in vitro and in vivo. Pharmacokinetic data indicate that GNPs reach their maximal concentrations at a time window of two to four hours post-injection, during which optimal radiation efficiency can be achieved. PEG-6-FDG-GNPs are thus novel nanoparticles that preferentially accumulate in targeted cancer cells where they act as potent radiosensitizing agents. Future research will aim to substitute the 18 F atom into the 6-FDG molecule so that the PEG-6-FDG-GNPs can also function as radiotracers for use in positron emission tomography scanning to aid cancer diagnosis and image guided radiation therapy planning.
Introduction
The use of gold nanoparticles (GNPs) represents a promising modality to achieve personalized cancer therapy, including the targeted delivery of anti-cancer chemotherapeutics such as methotrexate [1] , tamoxifen [2] and oxaliplatin [3] . GNPs have also been successfully applied in radio-frequency radiation [4] , thermal ablation [5, 6] and metal enhanced radiotherapy [7] . GNPs enhance the radiosensitivity of cancer cells by preferentially increasing the photoelectric absorption of low kilovoltage x-rays in tumour cells as compared to normal soft tissue adjacent to the tumour cells [8] [9] [10] [11] [12] . In our previous work, GNPs were utilized as a radiation sensitizer to significantly enhance radiation induced cancer cell death in breast cancer MCF-7 cells [12] , prostate cancer DU-140 cells [13] and ovary cancer Hela cells [14] . When prostate cancer DU-140 cells were treated with thiol-glucose coated GNPs (Glu-GNPs) for 6 h followed by x-ray irradiation, we observed a significant enhancement in radiosensitivity compared to the controls [15] .
Utilizing a thiol functional group, glucose molecules can be covalently linked to the GNP surface to form Glu-GNPs. Since cancer cells are known to metabolize glucose much faster than normal cells, Glu-GNPs have been shown to double the amount of intracellular uptake of Glu-GNP [13, 16] . Increased cancer cell uptake of Glu-GNPs compared to unbound GNPs leads to enhanced radiotherapeutic cytotoxicity in vitro [13, 14] and contrast enhancement of tumours in computerized axial tomography (CT) imaging [17, 18] . The mechanisms governing the Glu-GNP enhancement of radiotherapy have been investigated in vitro [15] . When combined with 2 Gy of orthovoltage irradiation, Glu-GNPs contribute to a 1.5-2.0 fold enhancement in growth inhibition of prostate cancer cells compared to those treated with x-rays alone [13] . This enhancement is likely caused by the generation of Auger electrons, a significant factor contributing to DNA damage that subsequently leads to cell apoptosis. Other potential mechanisms of the increased radiosensitivity include Glu-GNP induced acceleration of the G0/G1 phase and accumulation of cells in the G2/M phase [15] .
Glucose transport rates are estimated in a non-invasive manner in the physiological and pathological states by kinetic imaging using PET [19] . The common PET tracer is the glucose analogue, 2-( 18 F)fluoro-2-deoxy-D-glucose ( 18 F-2-FDG). In comparison with 18 F-2-FDG which is poorly absorbed by the intestines and kidneys, 18 F-labelled 6-fluoro-6-deoxy-D-glucose ( 18 F-6-FDG) is actively transported by the kidneys and intestines [20] . Therefore, 18 F-6-FDG can be utilized as a viable PET tracer for glucose transport in certain specific organs (e.g., the intestine) in which 18 F-2-FDG cannot perform in the same manner [20] .
To achieve the functions of imaging contrast and of image guided radiotherapy in a unified nanoparticle platform, we proposed to bind 18 F-6-FDG, a useful PET tracer and known radiosensitizer, to the GNP surface, thus forming 18 F-6-FDG-GNPs. A thiol group on the 6-FDG molecule was used to covalently bind the 18 F-6-FDG onto the surfaces of GNPs. In this paper, we examine the in vivo toxicological safety and pharmacokinetic profile of our multi-functional GNPs. The in vivo radiation enhancement was further evaluated in order to demonstrate the promising role that Glu-GNPs can play in treating cancers.
Materials and methods

General
Reagents and solvents were obtained from Sigma-Aldrich Chemical Corp. and Fisher Scientific Inc., and were used without further purification. The MTT cytotoxicity assay kit was purchased from Invitrogen (Burlington, Ontario, Canada). The pre-coated silica gel 60 F254 analytical plates for thin layer chromatography (TLC) were obtained from Merck (Kirkland, Québec, Canada). The flash column chromatography was performed on silica gel 60. 1 H-NMR spectra were recorded on a Varian 600 MHz spectrometer at 298 K in CDCl 3 or D 2 O.
Synthesis of 6-deoxy-
The synthesis process of thiol-6-FDG is shown in figure 1(A) .
Compound-1 was 1,2,3,4-tetra-O-acetyl-beta-D-glucopyranose (Sigma-Aldrich).
Compound-2 was 6-fluoro-1,2,3,4-tetra-O-acetyl-beta-Dglucose. Diethylaminosulfur trifluoride (DAST, 6.20 mmol) was added to a solution of compound-1 (1050 mg, 3.02 mmol) in anhydrous CH 2 Cl 2 (3 ml) at −41 • C. The solution was removed from the cooling bath and then stirred until it was warmed to room temperature. The solution was cooled to −10 • C and quenched by methanol (2 ml), then concentrated under reduced pressure. The residue was then subjected to flash column chromatography to yield compound-2 as a white powder. About 658 mg of final product was obtained with a percentage yield of 62.25%.
Compound-3 was 6-fluoro-2,3,4-tri-O-acetyl-1-S-acetyl-1-thiol-beta-D-glucopyranose. HSAc (20 µl, 0.27 mmol) and compound-2 (425 mg, 1.214 mmol) were added to a suspension of aluminum chloride (AlCl 3 ) (36 mg, 0.27 mmol) in anhydrous dichloromethane (CH 2 Cl 2 ) (2 ml). The mixture was refluxed for 20 min using an oil bath at 55 • C. The reaction mixture was then diluted with CH 2 Cl 2 (10 ml) and washed with saturated sodium bicarbonate (NaHCO 3 ) solution and brine. The crude product was subjected to silica gel flash column chromatography (hexanes/EtOAcratio 3:1) to obtain a white powder: compound-3 (34 mg, 65%), Rf 0.37 (Hex/EtOAc ratio 1:1). To identify this compound, 1 H-NMR (δ H ) was performed ( figure 1(B) Compound-4 was 1,6-dideoxy-6-fluoro-1-thiol-beta-Dglucose. Sodium methoxide (0.37 ml, 0.5M in CH 3 OH, 0.185 mmol, 2 equiv) was added to a solution of 6-fluoro-2,3,4-tri-O-acetyl-1-S-acetyl-1-thiol-beta-D-glucopyranose (compound-3) (367 mg, 1.0 equiv) in methanol (CH 3 OH) (1 ml). The solution was stirred at room temperature for 2 h and then the solvent was removed by a rotary evaporator. The residue was purified using a weak cation exchange column to obtain pure compound-4. 198 mg of final product was obtained with a yield of 53.95%. figure 1(B) ). Subsequent hydrolysis resulted in the production of thiol-6-FDG. Finally, when 18 F was used to replace the F in thiol-6-FDG, the thiol-6-18 FDG was produced.
Synthesis of 6-FDG-GNPs
The gold nanoparticles were synthesised [13] by the following three steps. (i) 2 ml of 25 mM tetrachloroauric acid (HAuCl 4 ) solution was added into 25 ml of deionized water in an ice bath with moderate stirring. (ii) 2 ml of 30 mM sodium borohydride (NaBH 4 ) was then added as a reductant to obtain GNPs without any capping agents. (iii) To functionalize the GNPs, 4 ml of 25 mM thiol-6-FDG was added to the previous gold solution to obtain functional 6-FDG-GNPs. Considering that the GNPs in step (ii) were vulnerable to aggregation, we added sodium citrate (TGS) as a capping agent. The average number of biomolecules (2.5 × 10 4 thiol-6-FDG) on each gold nanoparticle (20 nm in size) was calculated by measuring the gold-to-sulfur atom ratio with x-ray photoelectron spectroscopy (XPS) (Kratos Analytical).
2.5. Synthesis of PEG and thiol-6-FDG co-coated gold nanoparticles (PEG-FDG-GNPs)
In order to increase the biological half-life of the nanoparticles in vivo, a PEG-coated GNP was developed [23] . PEG-coated GNPs were prepared in two steps. Firstly, GNPs were synthesized using a well-known citrate reduction method [21] . Secondly, the GNPs were covalently linked to PEG by means of the thiol group of PEG-SH. PEG-SH was chosen as a surface reagent because it is biocompatible and spontaneously forms a chemisorbed surface layer on gold surfaces [22, 23] .
1.125 ml of 10 mM PEG (Sigma-Aldrich) was added into 1.125 ml of 20 mM thiol-6-FDG; the volume of PEG was adjusted in order to produce the desired molar ratio of FDG to PEG and the mixed solution was added into 30 ml of 20 nm diameter GNPs in a 50 ml centrifuge tube. The mixture was vortexed well and incubated at room temperature for 24 h. The GNPs bound with both thiol-6-FDG and PEG were then centrifuged at 9800 rpm for 20 min. After careful removal of the supernatant layer with a pipette, the concentrated GNP complex was diluted with deionized water to the desired concentration.
Characterization of the PEG-FDG-GNPs
The hydrodynamic particle size of the PEG-FDG-GNPs was measured by electrophoretic light scattering (ELS) (Beckman Coulter). The size of the PEG-coated GNPs in their dried state was measured using a Hitachi HF 3300 transmission electronic microscope (TEM). The gold concentration was measured by inductively coupled plasma mass spectrometry (ICP-MS) (PerkinElmer). The surface atom composition of the GNPs was assessed by Kratos Axis 165 XPS (Kratos Analytical).
Cell culture and cytotoxicity assay
The cell culture and culture conditions were as follows. The human breast cancer adenocarcinoma line MCF-7 was used in all experiments. The MCF-7 cell line was purchased from American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle medium (DMEM, Invitrogen) containing 10% foetal bovine serum (FBS) (Invitrogen), 100 IU penicillin G and 100 mg ml streptomycin (Sigma). The cells were incubated at 37 • C in a humidified 5% CO 2 atmosphere. The cytotoxicity induced by the GNPs with and without radiation was assessed by an MTT assay in 96-well plates following the instructions provided by the manufacturer.
The tumour-bearing mouse model
The tumour model was constructed as follows. MCF-7 cells were diluted in a culture medium (containing neither serum nor antibiotics) to a concentration of 5 × 10 6 cells per 0.2 ml. BALB/c female nude mice with intact ovaries at 4-5 weeks of age were used in this experiment. We chose the BALB/c female nude mouse model because these mice produce the necessary hormones for the growth of breast cancer cells and because they have been demonstrated to work well in conjunction with the human MCF-7 cell line. The mice were maintained in a specific pathogen-free environment and cared for in accordance with the institutional animal care guidelines. Each mouse was injected subcutaneously on the right flank with 5 × 10 6 cells. The tumour was permitted to grow for 10 days at which time the mean tumour volume (V) was approximately 0.74 cm 3 .
Bio-distribution of 6-FDG-GNPs and PEG-6-FDG-GNPs
On day one of the experiment, the mice were grouped into separate cages (n = 3). While under light anaesthesia (diethyl ether, Sigma-Aldrich), the animals were subjected to a tail-vein intravenous injection of 100 µl of GNP fluid (5 mg kg −1 ). The injections were well tolerated and no adverse effects were observed during the first 24 h. Twenty-four hours post-injection, the mice were anaesthetized with light ether and serum was collected in a heparinized glass tube via retro-orbital bleeding. Following the serum collection, the mice were sacrificed by cervical dislocation. Their organs including heart, liver, lungs, spleen, kidneys and stomach were collected for further analysis of the bio-distribution of the GNPs. The tissues were washed with normal saline and dried with blotting paper. The isolated tissues were weighed and stored at −20 • C and the serum was stored at 4-6 • C until the time of analysis. To assess the bio-distribution of the GNPs in tumour tissue, the tumour tissues were collected at 5, 10, 30, 120 and 240 min after the injection of the nanoparticles.
Five hundred milligrammes of each sample of GNPcontaining tumour tissue and murine organ tissue were minced by scissors and suspended in PBS to a final volume of 5 ml. 5 ml of 50% nitric acid (HNO 3 ) was added to each sample in order to lyse the cells, after which the samples were boiled until all sample tissues were dissolved. The lysis solution was then dried and 5 ml of 50% HNO 3 was added in order to normalize final solution volume to 5 ml. The gold mass in the lysis solution was measured using inductively coupled plasma mass spectrometry (ICP-MS) and the concentration of GNPs was calculated as gold mass and expressed as GNP mass per gramme of tissue [12] .
In vivo acute toxicity
We monitored the mice for acute toxicity at the following six different doses in a step-wise fashion: 35, 50, 67.6, 84.5, 101.5 and 120 mg Au kg −1 . Mice were grouped by GNP concentration (n = 6) and received tail-vein intravenous injections of 100 µl of 6-FDG-GNPs at the respective concentration while under ketamine anaesthesia. After 1 h, the mice received a second intravenous injection of 100 µl at the same concentration of 6-FDG-GNPs. Each dose level was delivered to a new set of mice in order to determine the acute toxicity for each injected dose level. Animal survival and morbidity was monitored three times a week using a morbidity score based on institutional guidelines.
6-FDG-GNP-based radiotherapy
Irradiation of cells: all irradiation treatments of cell cultures were carried out using a Pantak Therapax 3 Orthovoltage 244 Monitor Units/minute x-ray machine at 200 kVp using a 0.35 Cu + 1.5 Al filter. The MCF-7 cells were allowed to grow in 96-well plates overnight. After 75% confluence was reached, the old medium was replaced with 150 ml of freshly prepared medium containing GNPs at the desired concentrations. After 2 h of incubation to allow cellular uptake of the GNPs, the medium was replaced with fresh medium. The cells then received either a mock treatment for control or 2 Gy of radiation. After irradiation, the cultures were returned to incubation at 37 • C with 5% CO 2 until the time of analysis. The response of the cell culture to the GNPs with and without irradiation was assessed by the MTT assay following the manufacturer's instructions.
In vivo study
Based on the pharmacokinetic data of 6-FDG-GNPs determined in step 2.9, an optimized radiotherapeutic protocol was established. Twenty tumour-bearing BALB/c nude mice (four to five weeks of age) were used in this part of the study. The mice were divided into 4 groups: (1) the control group (n = 5) for which 200 µl saline alone was intravenously injected; (2) the experimental group receiving 6-FDG-GNPs (n = 15); (3) the experimental group treated with x-ray radiation alone (n = 15); and (4) the experimental group treated with both 6-FDG-GNPs and x-ray radiation (n = 5). All treatments were given while the mice were under anaesthesia with ketamine. The control group was only observed for the effect of the anaesthesia and injection procedures. Groups (2) and (4) received tail-vein intravenous injection of either GNPs or 6-FDG-GNPs. The 6-FDG-GNPs were administered at a starting concentration of 100 µg ml
for each fixed volume (0.2 ml) of IV solution. To assess the impact of the GNPs on radiotherapy, the animals in group (4) were irradiated using a Pantak Therapax 3 Orthovoltage 244 Monitor Units/minute x-ray machine at 200 kVp using a 0.35 Cu + 1.5 Al filter. Mice received either a mock treatment for control or 10 Gy of x-rays. Four weekly fractions of radiation were administrated to the mice in group 4. The irradiated mice were monitored as follows: continuously for the first 4 h, then every 1 h for eight hours, then every 12 h for two days and then once daily for two weeks. The time-course progression of tumour values was then plotted.
Statistics
All the experimental values were determined in triplicate.
All measured values including percentage of gold content were expressed as means and standard errors (SEs). The one-way analysis of variance (ANOVA) and Tukey multiple comparison post-test were used. Differences of less than 0.05 (p < 0.05) were considered statistically significant.
Results and discussion
We have demonstrated the effectiveness of GNPs as radiation dose enhancing agents for a number of cancers, including breast and prostate cancer lines, in vivo and in vitro [8] [9] [10] [11] [12] . Several mechanisms for GNP enhanced radiotherapy have been reported. Cancer cells take up more glucose compared to adjacent normal tissue due to their elevated metabolic growth rate. In our study, thiol-glucose was used to coat GNPs (Glu-GNPs) resulting in higher concentrations of GNPs in cancer cells compared to adjacent normal tissues [12] . However, Glu-GNPs have no imaging function. Therefore, we developed thiol-6-FDG-GNPs that can be eventually labelled by the radioisotope 18 F for PET imaging (supplementary supporting material available at stacks.iop. org/Nano/23/375101/mmedia). We are the first research group worldwide to report the pharmacokinetic and toxicological evaluation of 6-FDG-GNPs both in vitro and in vivo.
We first synthesized thiol- 19 fludeoxyglucose coated GNPs because 19 fludeoxyglucose can achieve the same function as 18 fludeoxyglucose but without radiation. As a result, we could use non-radioactive 19 fludeoxyglucose in the laboratory to independently test pharmacokinetics, toxicology and cancer killing efficiency. In our experiments, we used non-radioactive thiol- 19 fludeoxyglucose coated GNPs (thiol-6-FDG-GNPs) as a model compound for pharmacological study and evaluated its biological function in vivo. Finally, we optimized the bio-distribution of thiol-6-FDG-GNPs in cancer tissue for enhanced radiotherapy on breast cancerbearing mice.
Thiol-6-19 FDG and thiol-6-18 FDG
18 F-labelled 6-FDG has been approved as a valuable tracer that is actively transported by the kidneys as well as the intestines [20] . 6-FDG's ability to promote higher uptake by glucose-intensive tissue, including most cancers, makes it a useful molecule for diagnosing cancer via PET scan. We exploited 6-FDG's capacity for intercellular uptake and storage as a means to deliver GNPs into tumour cells by modifying the structural properties of 6-FDG so that it could be bound to the GNP surface. In order to bind 6-18 FDG to GNPs, we synthesized a thiol group on the 6-FDG molecule to form thiol-6-FDG (figures 1(A) and (B)). We used thiol-6-FDG as a model chemical for initial chemical and biological studies. After labelling 18 F to thiol-6-FDG, the thiol-6-18 FDG was used as a tracer for PET with its own specific bio-distribution (supplementary supporting material available at stacks.iop.org/Nano/23/375101/mmedia) that is 
. Synthesis of PEGylated 6-FDG-GNPs: FDG (A) and PEG (B) were coated onto GNPs (C) to form PEGylated 6-FDG-GNPs (D). The surface atom composition of the GNPs was assessed by Kratos Axis 165 x-ray photoelectron spectroscopy (XPS) (Kratos Analytical). (E) S-bind and (F) Au-bind.
different from 2-18 FDG, but similar to 6-18 FDG reported previously [20] .
Synthesis of 6-FDG-GNPs and PEG-6-FDG-GNPs
In this study, we employed non-radioactive thiol-19 fludeoxyglucose coated GNPs (thiol-6-FDG-GNPs) as a model compound to assess the bio-distribution in vivo. Although thiol- 19 Fludeoxyglucose coated GNPs do not carry the radioactive 18 F molecule that would enable the GNPs to be localized with a PET scan, thiol-19 fludeoxyglucose possesses the same molecular functional properties as 18 fludeoxyglucose without the potentially harmful effects of radiation. As such thiol-19 fludeoxyglucose provided us with the means to conduct our initial pharmacological assessments without the need for RADHAZ protective measures. The next step in our research process will be to radiolabel our multi-functional molecule with the 18 F atom in order to assess its suitability for diagnostic and radiation treatment planning imaging studies. Figure 2 shows a schematic diagram of the PEG and thiol-6-FDG mixture coated GNPs. Figure 2(A) shows transmission electron microscopy (TEM) images of the GNPs with average size of 20.17 + 1.23 nm (the TEM pictures of other nanoparticles are shown in the supplementary material available at stacks.iop.org/Nano/23/ 375101/mmedia). In order to identify the amount of PEG and thiol-6-FDG bound to each GNP ( figure 2(B) ), the nanoparticles were characterized using x-ray photoelectron spectroscopy (XPS). The average numbers of FDG and PEG combined bound to each GNP were 2.5 × 10 4 (for 10 nm) and 1.15 × 10 5 (for 20 nm) respectively, which were calculated by measuring the gold-to-sulfur atom ratio obtained by XPS (figures 2(E) and (F)). In the synthesis process, equal amounts of FDG and PEG were added for binding to the GNPs. Hence, in theory, the PEG to FDG ratio on the GNPs should be 1 to 1 since both PEG and FDG had equal chances of thiol-gold binding.
Bio-distribution of 6-FDG-GNPs
The 6-FDG-GNP suspension was administered by intravenous injection into mice. Figure 3(A) lists the bio-distribution of different sized 6-FDG-GNPs (without PEGylation) in various organ tissues (µg g −1 tissue) at 2 h after administration. For nanoparticles used for cancer therapy, the correlation of achieved levels of tumour accumulation with respect to the size of GNPs is of paramount importance. Our in vitro experiments demonstrated that the 20 nm 6-FDG-GNPs achieved the highest uptake in tumour tissue ( figure 3(C) ) and they were henceforth used in the study. The bio-distributions of 6-FDG-GNPs (20 nm) at different time intervals after injection are tabulated in table 1 and figure 4(B) . It is of interest that the data from the in vivo murine model indicate that 6-FDG-GNPs (20 nm) had also significantly accumulated in various organs ( figure 3(A) ). From the pharmacodynamic perspective, 6-FDG-GNPs accumulated in the liver and the spleen as soon as 5 min after the 6-FDG-GNP injection, at 4.35 and 1.62 µg g −1 respectively. At 2 h post-injection, the concentrations of nanoparticles in the liver and the spleen reached peak levels of 7.9 and 1.56 µg g −1 , respectively (table 1 and figure 3(B) ). The concentration of GNPs in the kidneys was 2.16 µg g −1 at 2 h post-injection, and gold concentrations were also detected in mice urine as soon as 10 min post-injection (table 1) . Therefore, although the 6-FDG-GNPs (20 nm) achieved a relatively high concentration in tumour tissue, selected normal organs accumulated a very high level of GNPs as well. In order to shift the bio-distribution of the 20 nm 6-FDG-GNPs preferentially to tumour cells over normal tissue, we PEGylated the 6-FDG-GNPs.
Bio-distribution of PEGylated 6-FDG-GNPs in normal tissue
PEG is known to reduce non-specific uptake of various molecules by the liver and the spleen. The coating of our 6-FDG-GNPs with PEG (PEG-FDG-GNPs) resulted in superior bio-distribution in various organs when compared to uncoated 6-FDG-GNPs. For instance, PEG significantly reduced non-specific uptake by the liver from 5.41 µg g −1 for 6-FDG-GNPs to 1.61 µg g −1 for PEG-FDG-GNPs. Decreased accumulation of gold in other organs, such as the spleen, the lung, the kidneys and muscle, was also observed ( figure 4(A) ). The significantly lower accumulations of PEG-FDG-GNPs in various organs may reduce the acute toxicity to these tissues; however, the organ toxicity induced by PEG-FDG-GNPs needs to be further investigated. It has been reported that nanoparticles administered into the blood stream, without surface modification, are eliminated from the circulation within seconds to minutes through the reticulo-endothelial system (RES) [25] . Similar results were observed in our experiments. Five minutes after the injection of thiol-6-FDG-GNPs into mice, GNPs accumulated in the liver and the spleen at concentrations of 4.35 µg g −1 and 1.62 µg g −1 , respectively (table 1). Two hours after injection, thiol-6-FDG-GNPs in the liver reached a peak concentration of 7.9 µg g −1 . This particularly high thiol-6-FDG-GNP concentration in the liver is attributable to the hepatic role of glucose-storage and reticulo-endothelial clearance. With FDG-GNPs, although the amount of gold accumulation in the tumour is twice that of adjacent normal tissue, it is relatively low at only one-fiftieth of that in the liver. To improve the bio-distribution of thiol-6-FDG-GNPs in vivo, we coated GNPs with both thiol-6-FDG and PEG (figure 2) because PEG helps GNPs to avoid the reticulo-endothelial system to improve GNP bio-distribution in vivo [24, 26] . In our studies, PEGylation of GNPs greatly improved their bio-distribution in vivo while decreasing accumulation in the liver and the spleen by 70.3%, and 52.1%, respectively ( figure 4(A) ). In the meantime, PEG-FDG-GNPs resulted in increased GNP concentration in cancer tissue by 108.8% when compared to 6-FDG-GNPs without PEGylation ( figure 4(B) ). With PEG-FDG-GNPs, the gold accumulation found in the tumour is about one-eighth of that in the liver. Cancer tissues would uptake 2.23 times more 6-FDG-GNPs and 6.09 times more PEG-FDG-GNPs than normal connective tissues, respectively ( figure 4(B) ).
PEGylation of the GNPs has, in a sense, improved the targeting of the GNPs by avoiding disproportionately high uptake by the reticulo-endothelial system. Although not clinically apparent at the dose levels employed in our study, this critical shift of the GNPs away from the liver and kidneys may be an important means in reducing radiation induced kidney and liver toxicity in the next step of our research when the dose levels of the GNPs may be potentially higher and we will be employing 18 F-labelled PEG-FDG-GNPs.
Bio-distribution of PEG-FDG-GNPs in cancer tissue
The ability for 18 F-labelled 6-FDG to promote higher uptake by glucose-intensive tissue (including most cancers) is useful for diagnosing cancer by PET scan [20] . We used this ability of 6-FDG to deliver more nanoparticles into cancer tissue as compared to adjacent normal tissue, enabling cancer to be distinguished from normal tissue.
This increased accumulation of GNPs in tumour tissue may have resulted from improved uptake due to FDG-and PEG-ligands. Compared to the cell uptake of GNPs by non-cancerous connective and muscle tissue (0.0433 µg g −1 ), the intra-tumour gold concentrations were almost doubled after the injection of either 6-FDG-GNPs (from 0.0433 to 0.0952 µg g −1 ) or PEG-GNPs (from 0.0433 to 0.1125 µg g −1 ) ( figure 4(B) ). PEGylation of the FDG-GNPs further improved the tumour uptake of the GNPs to 0.198 µg g −1 , which is almost five times more than citrate GNPs (i.e., 2.02 fold for PEG-GNPs, 2.33 fold for 6-FDG-GNPs and 6.09 fold for PEG-FDG-GNPs when compared to the adjacent normal connective and muscle tissue).
The kinetics of PEG-FDG-GNP uptake by cancerous tissue
The uptake of 20 nm PEG-FDG-GNPs by the MCF-7 breast adenocarcinoma in cancer-bearing mice was measured. 5 min post-injection, PEG-FDG-GNPs were initially observed in cancerous tissue with a concentration of 0.043 mg Au kg −1 of cancer tissue. As time elapsed, the concentration of GNPs steadily increased until a peak concentration of 0.1988 mg Au kg −1 was observed 2 h after injection. Subsequently, the gold concentration in cancer tissue remained appreciably high, at 0.127 mg Au kg −1 4 h after GNP injection ( figure 4(C) ). The dynamic change of GNP bio-distribution indicates that the GNPs reach their maximal concentrations at a time window of two to four hours post-injection ( figure 4(C) ). In order to achieve the optimal radiation efficiency, it will be logical to administer the radiation within this time window.
The timescale of the uptake and maintenance of peak levels of GNPs in tumour cells observed in the murine model experiments (2-4 h post-injection) is of clinical significance. Two to four hours of time represents a window of clinical feasibility that would easily allow modern day radiation oncology clinics enough time to assess, set up and deliver a daily prescribed dose of radiation following an IV injection of GNPs.
In vitro cytotoxicity and in vivo acute toxicity
In vitro tests were performed in order to study GNP induced cytotoxicity. The cancer cells were treated with chemicals for 2 h; only small cytotoxicities were observed and the cell cultures maintained cell survival rates of 96.4, 96.23 and 93.28%, for 6-FDGs, thiol-6-FDGs and thiol-6-FDG-GNPs respectively ( figure 5(A) ). Furthermore, the toxicity of thiol-6-FDG-GNPs was also evaluated in vivo. In our study, six doses, 35, 50, 67.6, 84.5, 101.5 and 120 mg Au kg −1 , were chosen. The highest concentration of 6-FDG-GNPs, 120 mg Au kg −1 , and all other lower dose levels did not induce apparent acute toxicity in the mice over a one-week observation period. The dose corresponding to an acute adverse response was never reached within the observed period, and thus the maximum tolerable dose of 6-FDG-GNPs was not reached.
No significant difference in cytotoxicity was observed between the control, 6-FDG and thiol-6-FDG (p < 0.05) (see figure 5) . Therefore, neither 6-FDG nor thiol-6-FDG induced significant cytotoxicity in MCF-7 cells and thiol-6-FDG may be used as a means to deliver GNPs to cancer tissue.
3.8. PEG-FDG-GNP enhanced radiotherapy sensitivity in vitro and in vivo 3.8.1. In vitro study.
MCF-7 cells with and without GNP pre-treatment were irradiated with 200 kVp x-rays at a dose of 10 Gy. We assessed the resulting cytotoxicity using the clonogenic assay five days after the irradiation. Responses of the MCF-7 cell line with and without x-ray treatment are shown in figure 5(B) . Following irradiation, MCF-7 cancer cells maintained a cell viability of 59.32% five days after irradiation ( figure 5(B) ). The addition of 15 nM PEG-FDG-GNPs (here the concentration refers to the gold concentration) induced enhanced radiation cell killing with a resultant cell survival rate of 32.34%. Figure 6 . 6-FDG-GNP enhanced radiotherapy sensitivity in vivo. A significantly superior tumour control is found with radiotherapy plus PEG-FDG-GNPs over radiotherapy alone treatment (P < 0.05). figure 6 show a significant reduction in the tumour size when x-ray radiation treatment was combined with PEG-FDG-GNP injections as compared to treatment with x-rays alone (P < 0.05).
In vivo study. The results displayed in
The in vitro and in vivo experiments comparing radiotherapy with and without GNPs have demonstrated that PEG-FDG-GNP molecules, when administered prior to radiotherapy, significantly enhance the cell-killing effects of x-ray radiation. In vitro, the relative reduction in surviving MCF-7 tumour cells in the cultures treated with both PEG-FDG-GNPs and radiation therapy was approximately 50% when compared to radiation alone. In vivo, the MCF-7 tumours in the murine model were also significantly smaller when treated with both PEG-FDG-GNPs and radiation as opposed to radiation alone. As such, the PEG-FDG-GNPs, despite having PEG and FDG molecules appended to the GNPs, maintain the much desired radiosensitizing properties that GNPs have been previously found to have [8] [9] [10] [11] [12] . Future research will be geared to investigating whether this same radiosensitizing effect is preserved across different cancer cell types as a means to determine the extent of the applicability of the PEG-FDG-GNPs.
Conclusion
The PEG-FDG-GNP represents a novel multi-functional nanoparticle with the ability to gain entry into and reside in breast adenocarinoma cells with greater affinity than citrate-GNPs alone. Furthermore, PEGylation simultaneously decreases hepatic and renal uptake of GNPs while increasing the relative amount of GNPs taken up by tumour cells. PEG-FDG-GNPs have also been shown in vitro and in vivo to act as a potent radiosensitizing agent that increases the lethality of radiation therapy towards breast cancer cells. In future investigations, we will use 18 F to replace 19 F for radiolabelling of PEG-FDG-GNPs in order to allow the PEG-FDG-GNPs to be used to aid in the diagnosis and image guided radiation treatment planning of tumours.
